Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

The GLP-1 agonist at the center of Pfizer’s upfront $4.9 billion buyout of Metsera last week has been tied to 14.1% weight loss at 28 weeks as well as “potentially class-leading tolerability,” ...

Pfizer has partnered with Sciwind Biosciences for a new type 2 diabetes drug. The deal could be worth up to 495 million dollars. This drug, ecnoglutide, is a GLP-1 receptor agonist. It helps control ...

Pfizer has acquired exclusive rights to commercialize an obesity therapy in China in a deal worth up to $495 million.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Pfizer joins six leading pharma companies helping launch and grow exceptional biotech ventures. BaseLaunch is a Basel-based incubator that partners with scientists and entrepreneurs to help launch and ...

Ecnoglutide is one of a growing number of GLP-1 drugs in Chinese market. Sciwind gained approved for it to be used in China ...

Pfizer (PFE) has been a behemoth in pharmaceuticals and drug development for decades, but lately has run into headwinds from vaccine sales, patent expiry, and more. That opens the door for smaller ...

Longtime Pfizer R&D chief Kathy Fernando, Ph.D., has left the Big Pharma behind to take on the role of chief business officer at San Diego biotech Replicate Bioscience. There, she’ll work to advance ...

These players are vying for positions in the billion-dollar weight loss drug market. Demand for weight loss drugs is soaring, suggesting there's room for more than one winner. 10 stocks we like better ...

Pfizer on Tuesday reported fourth-quarter results that topped estimates even amid dwindling demand for its Covid products, ...